Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair

Glia ◽  
2008 ◽  
Vol 56 (6) ◽  
pp. 686-698 ◽  
Author(s):  
Mark P. Marriott ◽  
Ben Emery ◽  
Holly S. Cate ◽  
Michele D. Binder ◽  
Dennis Kemper ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Leukemia Inhibitory Factor ◽  
Inhibitory Factor ◽  
Myelin Repair ◽  
Central Nervous System Demyelination

Anomalies Characteristic of Central Nervous System Demyelination

2018 ◽  
Vol 36 (1) ◽  
pp. 59-68 ◽  
Author(s):  
Christine Lebrun ◽  
Orhun H. Kantarci ◽  
Aksel Siva ◽  
Daniel Pelletier ◽  
Darin T. Okuda
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Demyelination

scholarly journals A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination

Brain ◽  
2010 ◽  
Vol 133 (10) ◽  
pp. 3017-3029 ◽  
Author(s):  
Maria Traka ◽  
Kavin Arasi ◽  
Robin L. Avila ◽  
Joseph R. Podojil ◽  
Athena Christakos ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Mouse Model ◽  
Adult Onset ◽  
Genetic Mouse Model ◽  
Central Nervous System Demyelination

scholarly journals Pathological findings in central nervous system demyelination associated with infliximab

2019 ◽  
Vol 26 (9) ◽  
pp. 1124-1129 ◽  
Author(s):  
Alicja Kalinowska-Lyszczarz ◽  
Mahboobeh Fereidan-Esfahani ◽  
Yong Guo ◽  
Claudia F Lucchinetti ◽  
W Oliver Tobin
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Tnf Alpha ◽  
Infliximab Treatment ◽  
Necrosis Factor Alpha ◽  
Immune Mediated ◽  
Central Nervous System Demyelination ◽  
Factor Alpha ◽  
Cns Demyelination ◽  
Necrosis Factor

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

Sign in / Sign up

Export Citation Format

Share Document